Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.79
AXGN's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: 0.79 )
AXGN' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 0.79

Equity to Asset 0.01
AXGN's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: 0.01 )
AXGN' s 10-Year Equity to Asset Range
Min: -4.23   Max: 0.91
Current: 0.01

-4.23
0.91
F-Score: 4
Z-Score: -3.48
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -87.62
AXGN's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -87.62 )
AXGN' s 10-Year Operating margin (%) Range
Min: -1447.95   Max: 64.05
Current: -87.62

-1447.95
64.05
Net-margin (%) -132.98
AXGN's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -132.98 )
AXGN' s 10-Year Net-margin (%) Range
Min: -1426.03   Max: 215.68
Current: -132.98

-1426.03
215.68
ROE (%) -10703.68
AXGN's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -10703.68 )
AXGN' s 10-Year ROE (%) Range
Min: -10703.68   Max: 136.03
Current: -10703.68

-10703.68
136.03
ROA (%) -52.58
AXGN's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -52.58 )
AXGN' s 10-Year ROA (%) Range
Min: -198.66   Max: 89.52
Current: -52.58

-198.66
89.52
ROC (Joel Greenblatt) (%) -247.66
AXGN's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -247.66 )
AXGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17616.67   Max: 265933.33
Current: -247.66

-17616.67
265933.33
Revenue Growth (%) -39.10
AXGN's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -39.10 )
AXGN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 477.6
Current: -39.1

0
477.6
EBITDA Growth (%) -47.80
AXGN's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -47.80 )
AXGN' s 10-Year EBITDA Growth (%) Range
Min: -47.8   Max: 196
Current: -47.8

-47.8
196
EPS Growth (%) -49.40
AXGN's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -49.40 )
AXGN' s 10-Year EPS Growth (%) Range
Min: -50.5   Max: 259.3
Current: -49.4

-50.5
259.3
» AXGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AXGN Guru Trades in

AXGN Guru Trades in

Q3 2013

AXGN Guru Trades in Q3 2013

Chuck Royce 12,000 sh (New)
» More
Q4 2013

AXGN Guru Trades in Q4 2013

Chuck Royce 12,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AXGN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 288.00
AXGN's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: 288.00 )
AXGN' s 10-Year P/B Range
Min: 0.69   Max: 486
Current: 288

0.69
486
P/S 3.55
AXGN's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: 3.55 )
AXGN' s 10-Year P/S Range
Min: 0.15   Max: 500
Current: 3.55

0.15
500
EV-to-EBIT 2.90
AXGN's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: 2.90 )
AXGN' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 206.3
Current: 2.9

0.1
206.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.70
AXGN's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: 0.70 )
AXGN' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 55
Current: 0.7

0.06
55
Earnings Yield (Greenblatt) 33.90
AXGN's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: 33.90 )
AXGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 6116
Current: 33.9

0.5
6116
Forward Rate of Return (Yacktman) -18.68
AXGN's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AXGN: -18.68 )
AXGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -33.9   Max: -0.2
Current: -18.68

-33.9
-0.2

Business Description

Industry: »
Compare: » details
AxoGen, Inc. is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves. The Company has developed and licensed technologies which are used in its products. Its product portfolio includes Avance Nerve Graft, which the Company believes is the first and only commercially available processed allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed), AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. AxoGen's products are used by surgeons during challenging surgical interventions to repair a wide variety of traumatic nerve injuries ranging from a simple laceration of a finger to a complex brachial plexus case. The Avance Nerve Graft, unlike hollow-tube conduits, provides surgeons with the essential three-dimensional structure of a natural nerve for bridging nerve discontinuities without the complication, expense and morbidity of autografting a nerve. Additionally, the Avance Nerve Graft has product and sales synergies with the AxoGuard Nerve Protector and AxoGuard Nerve Connector. AxoGuard products provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the patient's own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the nerve epineurium. AxoGen's products are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries.
» More Articles for AXGN

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide